Open-label use of highly purified CBD (Epidiolex®) in patients with CDKL5 deficiency disorder and Aicardi, Dup15q, and Doose syndromes

Orrin Devinsky*, Chloe Verducci, Elizabeth A. Thiele, Linda C Laux, Anup D. Patel, Francis Filloux, Jerzy P. Szaflarski, Angus Wilfong, Gary D. Clark, Yong D. Park, Laurie E. Seltzer, E. Martina Bebin, Robert Flamini, Robert T. Wechsler, Daniel Friedman

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

53 Scopus citations

Fingerprint Dive into the research topics of 'Open-label use of highly purified CBD (Epidiolex®) in patients with CDKL5 deficiency disorder and Aicardi, Dup15q, and Doose syndromes'. Together they form a unique fingerprint.

Medicine & Life Sciences